Angelika Beer (born 21 March 1952 in Wuppertal, West Germany) is a German politician affiliated with Alliance 90/The Greens. She served as a Member of the European Parliament (MEP) from 1999 until 2009, representing Germany. During her tenure, Beer was a member of the Committee on Civil Liberties, Justice and Home Affairs and participated in delegations related to EU‑USA relations and the ACP–EU Joint Parliamentary Assembly.
Early life and education
Beer studied law at the University of Bonn, graduating with a degree in jurisprudence. She subsequently practiced as a lawyer, focusing on criminal law and civil rights.
Political career
- German federal politics: Before her election to the European Parliament, Beer was active in regional politics within North Rhine‑Westphalia, holding positions within the Green Party’s state executive.
- European Parliament (1999‑2009): As an MEP, Beer served on the Committee on Civil Liberties, Justice and Home Affairs, where she worked on legislation concerning data protection, privacy, and fundamental rights. She was also a substitute member of the Committee on Legal Affairs. Beer was known for advocating stricter drug policy reforms, emphasizing public health approaches.
- Post‑parliamentary activities: After leaving the European Parliament, Beer continued involvement with civil‑society organizations, including serving on advisory boards focused on human rights and legal reform.
Political positions
Beer’s parliamentary work emphasized:
- Strengthening EU data‑protection standards.
- Enhancing consumer rights and digital privacy.
- Reforming drug legislation to prioritize prevention and treatment over criminalization.
Personal life
Angelika Beer resides in Germany. Details regarding her private life are limited in public sources, adhering to standard privacy norms for public figures.
References
- European Parliament archives (MEP profile: Angelika Beer).
- Alliance 90/The Greens party publications.
- News articles covering her legislative initiatives (e.g., data‑protection directives, drug policy debates).
